Leukemia & lymphoma

Keyphrases

Publications

volume 64, number 2, 2023

Daria Gaut, Caspian Oliai, Monica Mead
Outcomes of allogeneic hematopoietic stem cell transplantation in secondary central nervous system lymphoma: a case series. Leukemia & lymphoma 64 (2) (2023)
Hareth Nahi, Saad Z Usmani, Maria-Victoria Mateos-Manteca, Niels W C J van de Donk, Albert Oriol, Torben Plesner, Nibedita Bandyopadhyay, Peter Hellemans, Brenda Tromp, Ivo Nnane, Donna Zemlickis, Ajai Chari, Philippe Moreau
Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study. Leukemia & lymphoma 64 (2) (2023)
Chiara Rusconi, Chiara Rusconi
Putting the brain into mantle cell lymphoma. Leukemia & lymphoma 64 (2) (2023)
Chiara Rusconi, Chiara Rusconi
Putting the brain into mantle cell lymphoma. Leukemia & lymphoma 64 (2) (2023)
Hareth Nahi, Saad Z Usmani, Maria-Victoria Mateos-Manteca, Niels W C J van de Donk, Albert Oriol, Torben Plesner, Nibedita Bandyopadhyay, Peter Hellemans, Brenda Tromp, Ivo Nnane, Donna Zemlickis, Ajai Chari, Philippe Moreau
Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study. Leukemia & lymphoma 64 (2) (2023)
Chiara Rusconi, Chiara Rusconi
Putting the brain into mantle cell lymphoma. Leukemia & lymphoma 64 (2) (2023)
Hareth Nahi, Saad Z Usmani, Maria-Victoria Mateos-Manteca, Niels W C J van de Donk, Albert Oriol, Torben Plesner, Nibedita Bandyopadhyay, Peter Hellemans, Brenda Tromp, Ivo Nnane, Donna Zemlickis, Ajai Chari, Philippe Moreau
Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study. Leukemia & lymphoma 64 (2) (2023)
Daria Gaut, Caspian Oliai, Monica Mead
Outcomes of allogeneic hematopoietic stem cell transplantation in secondary central nervous system lymphoma: a case series. Leukemia & lymphoma 64 (2) (2023)
Daria Gaut, Caspian Oliai, Monica Mead
Outcomes of allogeneic hematopoietic stem cell transplantation in secondary central nervous system lymphoma: a case series. Leukemia & lymphoma 64 (2) (2023)
Hareth Nahi, Saad Z Usmani, Maria-Victoria Mateos-Manteca, Niels W C J van de Donk, Albert Oriol, Torben Plesner, Nibedita Bandyopadhyay, Peter Hellemans, Brenda Tromp, Ivo Nnane, Donna Zemlickis, Ajai Chari, Philippe Moreau
Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study. Leukemia & lymphoma 64 (2) (2023)
Hareth Nahi, Saad Z Usmani, Maria-Victoria Mateos-Manteca, Niels W C J van de Donk, Albert Oriol, Torben Plesner, Nibedita Bandyopadhyay, Peter Hellemans, Brenda Tromp, Ivo Nnane, Donna Zemlickis, Ajai Chari, Philippe Moreau
Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study. Leukemia & lymphoma 64 (2) (2023)
Chiara Rusconi, Chiara Rusconi
Putting the brain into mantle cell lymphoma. Leukemia & lymphoma 64 (2) (2023)
Daria Gaut, Caspian Oliai, Monica Mead
Outcomes of allogeneic hematopoietic stem cell transplantation in secondary central nervous system lymphoma: a case series. Leukemia & lymphoma 64 (2) (2023)
Daria Gaut, Caspian Oliai, Monica Mead
Outcomes of allogeneic hematopoietic stem cell transplantation in secondary central nervous system lymphoma: a case series. Leukemia & lymphoma 64 (2) (2023)
Chiara Rusconi, Chiara Rusconi
Putting the brain into mantle cell lymphoma. Leukemia & lymphoma 64 (2) (2023)

volume 64, number 3, 2023

Konstantinos Lontos, Anastasia Tsagianni, Mounzer Agha, Anastasios Raptis, Jing-Zhou Hou, Rafic Farah, Robert L Redner, Annie Im, Kathleen A Dorritie, Alison Sehgal, James Rossetti, Nidhi Aggarwal, Melissa Saul, Michael Boyiadzis, Nathanael Glen Bailey
Prognostic significance of blast immunophenotype on first post-induction bone marrow biopsy. Leukemia & lymphoma 64 (3) (2023)
Rebeca Jurado, Mercè Aren, Marc Sorigue
Should WE use flow cytometry to assess bone marrow involvement by lymphoma? Leukemia & lymphoma 64 (3) (2023)
Wei Xu, Shenmiao Yang, Keshu Zhou, Ling Pan, Zengjun Li, Sujun Gao, Daobin Zhou, Jianda Hu, Ru Feng, Haiwen Huang, Tingyu Wang, Dengju Li, Meng Ji, Haiyi Guo, Xia Zhao, Binghao Wu, Yiling Yu, Yu Wang, Jane Huang, William Novotny, Jianyong Li
Zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final results and correlative analysis of lymphocytosis. Leukemia & lymphoma 64 (3) (2023)
Jun Wang, Kai Sun, Wen-Min Chen, Xu Wang, Ling-Di Li, Yue Hao, Nan Xu, Hao Jiang, Lan-Ping Xu, Yu Wang, Xiao-Hui Zhang, Xiao-Jun Huang, Qian Jiang, Ya-Zhen Qin
The prognostic significance of CRLF2 expression at diagnosis in adult Ph-negative B-cell precursor acute lymphoblastic leukemia. Leukemia & lymphoma 64 (3) (2023)
David A Qualls, Ariela Noy, David J Straus, Matthew J Matasar, Craig H Moskowitz, Venkatraman Seshan, Ahmet Dogan, Gilles Andre Salles, Anas Younes, Andrew D Zelenetz, Connie Lee Batlevi
Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study. Leukemia & lymphoma 64 (3) (2023)
Jun Wang, Kai Sun, Wen-Min Chen, Xu Wang, Ling-Di Li, Yue Hao, Nan Xu, Hao Jiang, Lan-Ping Xu, Yu Wang, Xiao-Hui Zhang, Xiao-Jun Huang, Qian Jiang, Ya-Zhen Qin
The prognostic significance of CRLF2 expression at diagnosis in adult Ph-negative B-cell precursor acute lymphoblastic leukemia. Leukemia & lymphoma 64 (3) (2023)
Meng Lin, Xiaolong Wu, Lei Zhang, Ling Li, Xinhua Wang, Xiaorui Fu, Zhenchang Sun, Xudong Zhang, Linan Zhu, Hui Yu, Yu Chang, Feifei Nan, Jiaqin Yan, Zhiyuan Zhou, Cunzhen Shi, Mingzhi Zhang, Xin Li
Fotemustine, etoposide, cytarabine, and cyclophosphamide (FEAC) conditioning regimen for autologous stem cell transplantation in lymphoma. Leukemia & lymphoma 64 (3) (2023)
Meng Lin, Xiaolong Wu, Lei Zhang, Ling Li, Xinhua Wang, Xiaorui Fu, Zhenchang Sun, Xudong Zhang, Linan Zhu, Hui Yu, Yu Chang, Feifei Nan, Jiaqin Yan, Zhiyuan Zhou, Cunzhen Shi, Mingzhi Zhang, Xin Li
Fotemustine, etoposide, cytarabine, and cyclophosphamide (FEAC) conditioning regimen for autologous stem cell transplantation in lymphoma. Leukemia & lymphoma 64 (3) (2023)
Konstantinos Lontos, Anastasia Tsagianni, Mounzer Agha, Anastasios Raptis, Jing-Zhou Hou, Rafic Farah, Robert L Redner, Annie Im, Kathleen A Dorritie, Alison Sehgal, James Rossetti, Nidhi Aggarwal, Melissa Saul, Michael Boyiadzis, Nathanael Glen Bailey
Prognostic significance of blast immunophenotype on first post-induction bone marrow biopsy. Leukemia & lymphoma 64 (3) (2023)
Shuai Zhang, Ru Feng, Jiefei Bai, Shangyong Ning, Xiaodong Xu, Jie Sun, Meng Wu, Hui Liu
CDK7 inhibition induces apoptosis in acute myeloid leukemia cells and exerts synergistic antileukemic effects with azacitidine in vitro and in vivo . Leukemia & lymphoma 64 (3) (2023)
Rebeca Jurado, Mercè Aren, Marc Sorigue
Should WE use flow cytometry to assess bone marrow involvement by lymphoma? Leukemia & lymphoma 64 (3) (2023)
Shuai Zhang, Ru Feng, Jiefei Bai, Shangyong Ning, Xiaodong Xu, Jie Sun, Meng Wu, Hui Liu
CDK7 inhibition induces apoptosis in acute myeloid leukemia cells and exerts synergistic antileukemic effects with azacitidine in vitro and in vivo . Leukemia & lymphoma 64 (3) (2023)
Kimon V Argyropoulos, Umut Aypar, Mark D Ewalt, Mikhail Roshal, Ahmet Dogan, Filiz Sen
Chronic lymphocytic leukemia transdifferentiated to blastic neoplasm with T/plasmacytoid dendritic cell immunophenotype. Leukemia & lymphoma 64 (3) (2023)
Hoa Van Le, Kim Van Naarden Braun, Grzegorz S Nowakowski, David Sermer, John Radford, William Townsend, Hervé Ghesquières, Tobias Menne, Edit Porpaczy, Christopher P Fox, Claudia Schusterbauer, Fei Fei Liu, Lihua Yue, Marc De Benedetti, Jens Hasskarl
Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma. Leukemia & lymphoma 64 (3) (2023)
Shuai Zhang, Ru Feng, Jiefei Bai, Shangyong Ning, Xiaodong Xu, Jie Sun, Meng Wu, Hui Liu
CDK7 inhibition induces apoptosis in acute myeloid leukemia cells and exerts synergistic antileukemic effects with azacitidine in vitro and in vivo . Leukemia & lymphoma 64 (3) (2023)
Alex Bataller, Fadi G Haddad, Ghayas C Issa, Koiji Sasaki, Elias Jabbour, Gautam Borthakur, Alessandra Ferrajoli, Nicholas James Short
Sudden lymphoid blast crisis after tyrosine kinase inhibitor discontinuation in chronic phase chronic myeloid leukemia: cautionary tales for appropriate molecular monitoring. Leukemia & lymphoma 64 (3) (2023)
Rena Buckstein, Lisa Chodirker, Karen W L Yee, Michelle Geddes, Heather A Leitch, Grace Christou, Versha Banerji, Brian Leber, Dina Khalaf, Eve St-Hilaire, Nicholas Finn, Thomas Nevill, Mary-Margaret Keating, John Storring, Anne Parmentier, Aksharh Thambipillai, Derek Tang, Christopher Westcott, Chris Cameron, Paul Spin
The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry. Leukemia & lymphoma 64 (3) (2023)
David A Qualls, Ariela Noy, David J Straus, Matthew J Matasar, Craig H Moskowitz, Venkatraman Seshan, Ahmet Dogan, Gilles Andre Salles, Anas Younes, Andrew D Zelenetz, Connie Lee Batlevi
Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study. Leukemia & lymphoma 64 (3) (2023)
Swaratika Majumdar, Neha Sharma, Manju Sengar, Jayashree Thorat, Lingaraj Nayak, Avinash Bonda, Bhausaheb Bagal, Akhil Rajendra, Amit Sethi, Hasmukh Jain
A phase II study to evaluate the efficacy of low-dose rasburicase (1.5mg) in adolescent and adult acute leukemia and high-grade lymphomas with tumor lysis syndrome. Leukemia & lymphoma 64 (3) (2023)
Kimon V Argyropoulos, Umut Aypar, Mark D Ewalt, Mikhail Roshal, Ahmet Dogan, Filiz Sen
Chronic lymphocytic leukemia transdifferentiated to blastic neoplasm with T/plasmacytoid dendritic cell immunophenotype. Leukemia & lymphoma 64 (3) (2023)
Prajwal Dhakal, Elizabeth Lyden, Utsav Joshi, Avantika Pyakuryal, Kah Poh Loh, Heidi Klepin, Vijaya Raj Bhatt
Comorbidity burden and outcomes of older adults with acute promyelocytic leukemia: a National Cancer Database analysis of 2221 patients. Leukemia & lymphoma 64 (3) (2023)
David A Qualls, Ariela Noy, David J Straus, Matthew J Matasar, Craig H Moskowitz, Venkatraman Seshan, Ahmet Dogan, Gilles Andre Salles, Anas Younes, Andrew D Zelenetz, Connie Lee Batlevi
Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study. Leukemia & lymphoma 64 (3) (2023)
Jun Wang, Kai Sun, Wen-Min Chen, Xu Wang, Ling-Di Li, Yue Hao, Nan Xu, Hao Jiang, Lan-Ping Xu, Yu Wang, Xiao-Hui Zhang, Xiao-Jun Huang, Qian Jiang, Ya-Zhen Qin
The prognostic significance of CRLF2 expression at diagnosis in adult Ph-negative B-cell precursor acute lymphoblastic leukemia. Leukemia & lymphoma 64 (3) (2023)
Prajwal Dhakal, Elizabeth Lyden, Utsav Joshi, Avantika Pyakuryal, Kah Poh Loh, Heidi Klepin, Vijaya Raj Bhatt
Comorbidity burden and outcomes of older adults with acute promyelocytic leukemia: a National Cancer Database analysis of 2221 patients. Leukemia & lymphoma 64 (3) (2023)
Rena Buckstein, Lisa Chodirker, Karen W L Yee, Michelle Geddes, Heather A Leitch, Grace Christou, Versha Banerji, Brian Leber, Dina Khalaf, Eve St-Hilaire, Nicholas Finn, Thomas Nevill, Mary-Margaret Keating, John Storring, Anne Parmentier, Aksharh Thambipillai, Derek Tang, Christopher Westcott, Chris Cameron, Paul Spin
The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry. Leukemia & lymphoma 64 (3) (2023)
Swaratika Majumdar, Neha Sharma, Manju Sengar, Jayashree Thorat, Lingaraj Nayak, Avinash Bonda, Bhausaheb Bagal, Akhil Rajendra, Amit Sethi, Hasmukh Jain
A phase II study to evaluate the efficacy of low-dose rasburicase (1.5mg) in adolescent and adult acute leukemia and high-grade lymphomas with tumor lysis syndrome. Leukemia & lymphoma 64 (3) (2023)
Wei Xu, Shenmiao Yang, Keshu Zhou, Ling Pan, Zengjun Li, Sujun Gao, Daobin Zhou, Jianda Hu, Ru Feng, Haiwen Huang, Tingyu Wang, Dengju Li, Meng Ji, Haiyi Guo, Xia Zhao, Binghao Wu, Yiling Yu, Yu Wang, Jane Huang, William Novotny, Jianyong Li
Zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final results and correlative analysis of lymphocytosis. Leukemia & lymphoma 64 (3) (2023)
Panayotis Kaloyannidis, Mohammed Al Zayer, Mohammed Al Darweesh, Majed Al Batran, Ayed Al Garni, Abdulrahman Al Naim, Hani Al Hashmi, Solaf Kanfar
Brentuximab vedotin plus bendamustine versus platinum-based regimens as 1st salvage therapy and 'bridge' to autologous hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma. Leukemia & lymphoma 64 (3) (2023)
Hoa Van Le, Kim Van Naarden Braun, Grzegorz S Nowakowski, David Sermer, John Radford, William Townsend, Hervé Ghesquières, Tobias Menne, Edit Porpaczy, Christopher P Fox, Claudia Schusterbauer, Fei Fei Liu, Lihua Yue, Marc De Benedetti, Jens Hasskarl
Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma. Leukemia & lymphoma 64 (3) (2023)
Alex Bataller, Fadi G Haddad, Ghayas C Issa, Koiji Sasaki, Elias Jabbour, Gautam Borthakur, Alessandra Ferrajoli, Nicholas James Short
Sudden lymphoid blast crisis after tyrosine kinase inhibitor discontinuation in chronic phase chronic myeloid leukemia: cautionary tales for appropriate molecular monitoring. Leukemia & lymphoma 64 (3) (2023)
Panayotis Kaloyannidis, Mohammed Al Zayer, Mohammed Al Darweesh, Majed Al Batran, Ayed Al Garni, Abdulrahman Al Naim, Hani Al Hashmi, Solaf Kanfar
Brentuximab vedotin plus bendamustine versus platinum-based regimens as 1st salvage therapy and 'bridge' to autologous hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma. Leukemia & lymphoma 64 (3) (2023)

volume 64, number 4, 2023

Luca Fischer, Martin Dreyling
Follicular lymphoma: an update on biology and optimal therapy. Leukemia & lymphoma 64 (4) (2023)
Tadeusz Robak, Jaroslaw D Kasprzak, Dorota Jesionek-Kupnicka, Michał Soin, Paweł Robak
Small lymphocytic lymphoma in the heart twenty years after lymphoma diagnosis. Leukemia & lymphoma 64 (4) (2023)

volume 63, number 14, 2023